BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiang SS, Weng DS, Wang QJ, Pan K, Zhang YJ, Li YQ, Li JJ, Zhao JJ, He J, Lv L. Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma. J Transl Med. 2014;12:273. [PMID: 25260879 DOI: 10.1186/s12967-014-0273-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Shao Q, He J, Chen Z, Wu C. Prognostic role of galectins expression in patients with hepatic cancer: A meta-analysis. Medicine (Baltimore) 2020;99:e19622. [PMID: 32282710 DOI: 10.1097/MD.0000000000019622] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
2 Cao Z, Sun B, Zhao X, Zhang Y, Gu Q, Liang X, Dong X, Zhao N. The Expression and Functional Significance of Runx2 in Hepatocellular Carcinoma: Its Role in Vasculogenic Mimicry and Epithelial-Mesenchymal Transition. Int J Mol Sci 2017;18:E500. [PMID: 28264434 DOI: 10.3390/ijms18030500] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
3 Manzi M, Bacigalupo ML, Carabias P, Elola MT, Wolfenstein-Todel C, Rabinovich GA, Espelt MV, Troncoso MF. Galectin-1 Controls the Proliferation and Migration of Liver Sinusoidal Endothelial Cells and Their Interaction With Hepatocarcinoma Cells. J Cell Physiol. 2016;231:1522-1533. [PMID: 26551914 DOI: 10.1002/jcp.25244] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
4 Gao N, Wang X, Sun J, Yu W, Li X. Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens. Ann Hematol 2017;96:711-8. [DOI: 10.1007/s00277-017-2948-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Del Turco S, De Simone P, Ghinolfi D, Gaggini M, Basta G. Comparison between galectin-3 and YKL-40 levels for the assessment of liver fibrosis in cirrhotic patients. Arab J Gastroenterol 2021:S1687-1979(21)00015-0. [PMID: 34088622 DOI: 10.1016/j.ajg.2021.03.002] [Reference Citation Analysis]
6 Nassar ES, Elkalbashawy YA, Kamal A, Zakaria NHE. Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development. Clin Exp Hepatol 2021;7:74-8. [PMID: 34027118 DOI: 10.5114/ceh.2021.104385] [Reference Citation Analysis]
7 Gao N, Yu WZ, Guo NJ, Wang XX, Sun JR. Clinical significance of galectin-3 in patients with adult acute myeloid leukemia: a retrospective cohort study with long-term follow-up and formulation of risk scoring system. Leuk Lymphoma 2017;58:1394-402. [PMID: 27736291 DOI: 10.1080/10428194.2016.1243677] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
8 Dubé-Delarosbil C, St-Pierre Y. The emerging role of galectins in high-fatality cancers. Cell Mol Life Sci 2018;75:1215-26. [PMID: 29119229 DOI: 10.1007/s00018-017-2708-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
9 Yu H, Zhu X, Lin H, Pan H, Zhao F, Zhu M, Sun L, Chai W, Yao M, Yan M. A new risk model comprising genes highly correlated with CD133 identifies different tumor-immune microenvironment subtypes impacting prognosis in hepatocellular carcinoma. Aging (Albany NY) 2020;12:12234-50. [PMID: 32564007 DOI: 10.18632/aging.103409] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Kong F, Jin M, Cao D, Jia Z, Liu Y, Jiang J. Galectin-3 not Galectin-9 as a candidate prognosis marker for hepatocellular carcinoma. PeerJ 2020;8:e9949. [PMID: 32995093 DOI: 10.7717/peerj.9949] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
11 Ghapanchi J, Andisheh-tadbir A, Torkaman P, Malekzadeh M, Mardani M. Evaluation of the serum levels of galectin-3 in patients with oral lichen planus disease. Oral Dis 2019;25:466-70. [DOI: 10.1111/odi.13012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Liu Y, Xie L, Wang D, Li D, Xu G, Wang L, Zhou H, Yu Y, Lin Z, Lu H. Galectin-3 and β-catenin are associated with a poor prognosis in serous epithelial ovarian cancer. Cancer Manag Res 2018;10:3963-71. [PMID: 30310317 DOI: 10.2147/CMAR.S171146] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 3.3] [Reference Citation Analysis]
13 Al-Maghrabi J, Abdelrahman AS, Ghabrah T, Butt NS, Al-Maghrabi B, Khabaz MN. Immunohistochemical expression of galectin-3 is significantly associated with grade, stage and differentiation of endometrial carcinomas. Pathol Res Pract 2017;213:348-52. [PMID: 28215640 DOI: 10.1016/j.prp.2017.01.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
14 Tummala KS, Brandt M, Teijeiro A, Graña O, Schwabe RF, Perna C, Djouder N. Hepatocellular Carcinomas Originate Predominantly from Hepatocytes and Benign Lesions from Hepatic Progenitor Cells. Cell Rep 2017;19:584-600. [PMID: 28423321 DOI: 10.1016/j.celrep.2017.03.059] [Cited by in Crossref: 62] [Cited by in F6Publishing: 48] [Article Influence: 15.5] [Reference Citation Analysis]
15 Lin Y, Lin G, Fang W, Zhu H, Chu K. Increased expression of annexin A1 predicts poor prognosis in human hepatocellular carcinoma and enhances cell malignant phenotype. Med Oncol 2014;31:327. [PMID: 25412936 DOI: 10.1007/s12032-014-0327-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
16 Dong R, Zhang M, Hu Q, Zheng S, Soh A, Zheng Y, Yuan H. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). Int J Mol Med 2018;41:599-614. [PMID: 29207027 DOI: 10.3892/ijmm.2017.3311] [Cited by in Crossref: 40] [Cited by in F6Publishing: 55] [Article Influence: 10.0] [Reference Citation Analysis]
17 Xing M, Wang X, Kiken RA, He L, Zhang JY. Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment. Int J Mol Sci 2021;22:6139. [PMID: 34200243 DOI: 10.3390/ijms22116139] [Reference Citation Analysis]
18 Jiang SS, Weng DS, Jiang L, Zhang YJ, Pan K, Pan QZ, Chen CL, Zhao JJ, Zhang XF, Zhang HX, Tang Y, Zhou ZQ, Chen MS, Xia JC. The clinical significance of preoperative serum cholesterol and high-density lipoprotein-cholesterol levels in hepatocellular carcinoma. J Cancer 2016;7:626-32. [PMID: 27076843 DOI: 10.7150/jca.13837] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
19 Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol. 2015;21:10584-10597. [PMID: 26457018 DOI: 10.3748/wjg.v21.i37.10584] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 41] [Article Influence: 7.4] [Reference Citation Analysis]
20 Norton P, Comunale MA, Herrera H, Wang M, Houser J, Wimmerova M, Romano PR, Mehta A. Development and application of a novel recombinant Aleuria aurantia lectin with enhanced core fucose binding for identification of glycoprotein biomarkers of hepatocellular carcinoma. Proteomics 2016;16:3126-36. [PMID: 27650323 DOI: 10.1002/pmic.201600064] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
21 Zhang X, Wang Z, Tian L, Xie J, Zou G, Jiang F. Increased Expression of FGF19 Contributes to Tumor Progression and Cell Motility of Human Thyroid Cancer. Otolaryngol Head Neck Surg 2016;154:52-8. [PMID: 26450751 DOI: 10.1177/0194599815609534] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
22 Shimura T, Kofunato Y, Okada R, Yashima R, Koyama Y, Araki K, Kuwano H, Takenoshita S. Intranuclear accumulation of galectin-3 is an independent prognostic factor for patients with distal cholangiocarcinoma. Oncol Lett 2017;14:819-29. [PMID: 28693238 DOI: 10.3892/ol.2017.6252] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Wang Y, Liu S, Tian Y, Wang Y, Zhang Q, Zhou X, Meng X, Song N. Prognostic role of galectin-3 expression in patients with solid tumors: a meta-analysis of 36 eligible studies. Cancer Cell Int 2018;18:172. [PMID: 30410421 DOI: 10.1186/s12935-018-0668-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
24 Sturgill ER, Rolig AS, Linch SN, Mick C, Kasiewicz MJ, Sun Z, Traber PG, Shlevin H, Redmond WL. Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity. Oncoimmunology 2021;10:1892265. [PMID: 33717655 DOI: 10.1080/2162402X.2021.1892265] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Wang M, Tian F, Ying W, Qian X. Quantitative proteomics reveal the anti-tumour mechanism of the carbohydrate recognition domain of Galectin-3 in Hepatocellular carcinoma. Sci Rep 2017;7:5189. [PMID: 28701735 DOI: 10.1038/s41598-017-05419-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
26 Arbelaiz A, Azkargorta M, Krawczyk M, Santos-laso A, Lapitz A, Perugorria MJ, Erice O, Gonzalez E, Jimenez-agüero R, Lacasta A, Ibarra C, Sanchez-campos A, Jimeno JP, Lammert F, Milkiewicz P, Marzioni M, Macias RI, Marin JJ, Patel T, Gores GJ, Martinez I, Elortza F, Falcon-perez JM, Bujanda L, Banales JM. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma: Arbelaiz et al. Hepatology 2017;66:1125-43. [DOI: 10.1002/hep.29291] [Cited by in Crossref: 116] [Cited by in F6Publishing: 105] [Article Influence: 29.0] [Reference Citation Analysis]
27 Ajani JA, Estrella JS, Chen Q, Correa AM, Ma L, Scott AW, Jin J, Liu B, Xie M, Sudo K, Shiozaki H, Badgwell B, Weston B, Lee JH, Bhutani MS, Onodera H, Suzuki K, Suzuki A, Ding S, Hofstetter WL, Johnson RL, Bresalier RS, Song S. Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors. Br J Cancer 2018;118:52-61. [PMID: 29136404 DOI: 10.1038/bjc.2017.388] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
28 Zhang Y, Liu G, Wu S, Jiang F, Xie J, Wang Y. Zinc finger E-box-binding homeobox 1: its clinical significance and functional role in human thyroid cancer. Onco Targets Ther 2016;9:1303-10. [PMID: 27099512 DOI: 10.2147/OTT.S96723] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
29 Li G, Gao Y, Cui L, Wu L, Yang X, Chen J. Anguilla japonica lectin 1 delivery through adenovirus vector induces apoptotic cancer cell death through interaction with PRMT5: AJL1 induces apoptotic cancer cell death. J Gene Med 2016;18:65-74. [DOI: 10.1002/jgm.2878] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]